Claims

1. A kit comprising: (a) a first immunogenic composition comprising a glycoconjugate from *S. pneumoniae* serotype 15B wherein said serotype 15B glycoconjugate has a molecular weight of between 1000 kDa and 20,000 kDa, the ratio (w/w) of serotype 15B capsular polysaccharide to carrier protein in serotype 15B glycoconjugate is between 0.5 and 3 and wherein said serotype 15B glycoconjugate comprises at least 0.1 mM acetate per mM serotype 15B capsular polysaccharide, a glycoconjugate from *S. pneumoniae* serotype 22F wherein said serotype 22F glycoconjugate has a molecular weight of between 1000 kDa and 12,500 kDa, the ratio (w/w) of serotype 22F capsular polysaccharide to carrier protein in serotype 22F glycoconjugate is between 0.5 and 2 and wherein said serotype 22F glycoconjugate comprises at least 0.1 mM acetate per mM serotype 22F capsular polysaccharide, a glycoconjugate from *S. pneumoniae* serotype 33F wherein, said serotype 33F glycoconjugate has a molecular weight of between 50 kDa and 20,000 kDa, the ratio (w/w) of serotype 33F capsular polysaccharide to carrier protein in serotype 33F glycoconjugate is between 0.2 and 4 and wherein said serotype 33F glycoconjugate comprises at least 0.1 mM acetate per mM serotype 33F capsular polysaccharide, a glycoconjugate from *S. pneumoniae* serotype 12F wherein, said serotype 12F glycoconjugate has a molecular weight of between 50 kDa and 20,000 kDa the ratio (w/w) of serotype 12F capsular polysaccharide to carrier protein in serotype 12F glycoconjugate is between 0.2 and 4, a glycoconjugate from *S. pneumoniae* serotype 10A wherein, said serotype 10A glycoconjugate has a molecular weight of between 50 kDa and 20,000 kDa, the ratio (w/w) of serotype 10A capsular polysaccharide to carrier protein in serotype 10A glycoconjugate is between 0.5 and 3, a glycoconjugate from *S. pneumoniae* serotype 11A wherein, said serotype 11A glycoconjugate has a molecular weight of between 50 kDa and 20,000 kDa, the ratio (w/w) of serotype 11A capsular polysaccharide to carrier protein in serotype 11A glycoconjugate is between 0.2 and 4 and a glycoconjugate from *S. pneumoniae* serotype 8 wherein, said serotype 8 glycoconjugate has a molecular weight of between 50 kDa and 20,000 kDa, the ratio (w/w) of serotype 8 capsular polysaccharide to carrier protein in serotype 8 glycoconjugate is between 0.2 and 4, wherein said composition is a 7-valent pneumococcal conjugate composition and wherein said glycoconjugates are

individually conjugated to CRM_{197}; and (b) a second immunogenic composition comprising glycoconjugates from *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F and wherein said glycoconjugates are individually conjugated to CRM_{197}, for concurrent, concomitant or sequential administration of the first and second immunogenic compositions.

2. The kit of claim 1, wherein said first immunogenic composition further comprises at least one adjuvant.

3. The kit of any one of claims 1-2, wherein said second immunogenic composition is a 13-valent pneumococcal conjugate composition wherein said 13 conjugates consists of glycoconjugates from *S. pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F individually conjugated to CRM_{197}.

4. The kit of any one of claims 1-3, wherein said second immunogenic composition further comprises at least one adjuvant.

5. The kit of any one of claims 1-4 for use in a method of concomitant administration of the first and second immunogenic compositions.

6. The kit of any one of claims 1-4 for use in a method of concurrent administration of the first and second immunogenic compositions.

7. The kit of any one of claims 5-6 wherein the schedule of vaccination of said simultaneous, concomitant or concurrent administration is a multiple dose schedule.

8. The kit of claim 7 wherein said multiple dose schedule consists of at least one dose (e.g., 1, 2 or 3 doses) in the first year of age followed by at least one toddler dose.

9. The kit of any one of claims 1-4 for use in a method of sequential administration of the first and second immunogenic compositions.

10. The kit of claim 9 wherein the schedule of vaccination of said sequential administration consists of a series of 2, 3, 4, 5, 6, 7 or 8 doses.

11. The kit of of any one of claims 9-10 wherein the schedule of vaccination consists of the sequential administration of:

(a) the first immunogenic composition and

(b) the concomitant or concurrent administration of the first immunogenic composition with the second immunogenic composition.

12. The kit of any one of claims 9-10 wherein the schedule of vaccination consists of the sequential administration of:

(a) the second immunogenic composition and

(b) the concomitant or concurrent administration of the first immunogenic composition with the second immunogenic composition.